CaMKII inhibitor AIP

Also Known As:

(Ala9)-autocamtide 2-related inhibitory peptide trifluoroacetate salt; AIP CaMKII inhibitor; Ala(9)-autocamtide 2-related inhibitory peptide; Myr-Lys-Lys-Ala-Leu-Arg-Arg-Gln-Glu-Ala-Val-Asp-Ala-Leu-OH; autocamtide-2-related inhibitory peptide

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - CaMKII inhibitor AIP: 6

Experts

1.	Maier, Lars S: 2 articles (08/2013 - 02/2006)
2.	Wagner, Stefan: 2 articles (08/2013 - 02/2006)
3.	Ding, Fan: 1 article (12/2020)
4.	Hao, Liying: 1 article (12/2020)
5.	Li, Jingyuan: 1 article (12/2020)
6.	Liu, Yan: 1 article (12/2020)
7.	Sun, Xuefei: 1 article (12/2020)
8.	Wang, Siqi: 1 article (12/2020)
9.	Zhang, Jie: 1 article (12/2020)
10.	Zhao, Meimi: 1 article (12/2020)

Related Diseases

1.	Neuralgia (Stump Neuralgia) 02/01/2011 - "The aim of this study was to examine the effect of the CaMKII inhibitor AIP on the association of CaMKII and CREB in a partial sciatic nerve ligation neuropathic pain model in rats. "
2.	Infections 02/03/2006 - "Diastolic SR Ca2+ leak assessed by Ca2+ spark frequency (normalized to SR Ca2+ load) was increased by 88% in CaMKIIdeltaC versus LacZ myocytes (P<0.05; in an multiplicity-of-infection-dependent manner), an effect blocked by CaMKII inhibitors KN-93 and autocamtide-2-related inhibitory peptide. "
3.	Hypertrophy 12/01/2020 - "Isoproterenol (ISO) was used to induce cardiomyocyte hypertrophy, and autocamtide-2-related inhibitory peptide (AIP) was added as a treatment. "
4.	Hyperalgesia 05/26/2009 - "Axotomized neurons from rats made hyperalgesic by SNL lost sensitivity to the myristoylated form of autocamtide-2-related inhibitory peptide (AIPm), a pseudosubstrate blocker of CaMKII, whereas axotomized neurons from SNL animals that failed to develop hyperalgesia showed normal IK(ATP) inhibition by AIPm. "
5.	Heart Failure 08/01/2013 - "In contrast, after five weeks animals developed heart failure with prolonged APDs and slowed INaL decay time which could be normalized by addition of the INaL inhibitor ranolazine (Ran) or by the Ca/calmodulin-dependent protein kinase II (CaMKII) inhibitor AIP. "

Related Drugs and Biologics

1.	Calcium-Calmodulin-Dependent Protein Kinase Type 2
2.	MEF2 Transcription Factors
3.	Calcium-Calmodulin-Dependent Protein Kinases
4.	Protein Kinase C
5.	Peptides (Polypeptides)
6.	Atrial Natriuretic Factor (ANF)
7.	Isoproterenol (Isoprenaline)
8.	Histone Deacetylases (Histone Deacetylase)
9.	Calmodulin (Calcium-Dependent Activator Protein)
10.	Adenosine Triphosphate (ATP)

Related Therapies and Procedures

1.	Ligation